IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally.
Adequate balance sheet and overvalued.
Share Price & News
How has IBEX Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IBT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IBT underperformed the German Biotechs industry which returned 9% over the past year.
Return vs Market: IBT underperformed the German Market which returned 14.4% over the past year.
Price Volatility Vs. Market
How volatile is IBEX Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is IBEX Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IBT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IBT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IBT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IBT is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IBT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IBT is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.6x).
How is IBEX Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IBEX Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine IBEX Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- IBEX Technologies competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has IBEX Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IBT is currently unprofitable.
Growing Profit Margin: IBT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IBT is unprofitable, and losses have increased over the past 5 years at a rate of -3.9% per year.
Accelerating Growth: Unable to compare IBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: IBT has a negative Return on Equity (-14.96%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is IBEX Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: IBT's short term assets (CA$3.6M) exceed its short term liabilities (CA$823.9K).
Long Term Liabilities: IBT's short term assets (CA$3.6M) exceed its long term liabilities (CA$1.4M).
Debt to Equity History and Analysis
Debt Level: IBT's debt to equity ratio (14.7%) is considered satisfactory.
Reducing Debt: IBT's debt to equity ratio has reduced from 26.6% to 14.7% over the past 5 years.
Inventory Level: IBT has a high level of physical assets or inventory.
Debt Coverage by Assets: IBT's debt is covered by short term assets (assets are 3.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IBT has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: IBT has been profitable on average in the past, therefore cash runway is not a concern.
What is IBEX Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IBT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IBT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IBT's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Paul Baehr (76yo)
Mr. Paul Baehr has been the Chairman and Chief Executive Officer of IBEX Technologies, Inc. since October 1995 and serves as its President. Mr. Baehr serves as the President of Bio-Research Products, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD186.27K) is below average for companies of similar size in the German market ($USD412.57K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
|Lead Director||0yrs||CA$27.63k||0.27% CA$7.1k|
|Independent Director||12.3yrs||CA$25.31k||0.087% CA$2.3k|
|Independent Director||2.3yrs||CA$23.30k||no data|
|Independent Director||2.3yrs||CA$20.97k||no data|
Experienced Board: IBT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IBEX Technologies Inc.'s company bio, employee growth, exchange listings and data sources
- Name: IBEX Technologies Inc.
- Ticker: IBT
- Exchange: DB
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$3.716m
- Listing Market Cap: CA$2.596m
- Shares outstanding: 24.77m
- Website: https://www.ibex.ca
- IBEX Technologies Inc.
- 5485 Paré Street
- Suite 100
- H4P 1P7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IBT||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Mar 1996|
|IBT||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 1996|
|IBXN.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Mar 1996|
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 20:58|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.